What question did this study set out to answer?

Assess CKD screening rates and testing patterns for eGFR and uACR in adults with Type 2 Diabetes.

June 7, 2026

1408-P: Chronic Kidney Disease (CKD) Screening in Type 2 Diabetes (T2DM): A Real-World Analysis of Estimated Glomerular Filtration Rate (eGFR) and Urine Albumin–Creatinine Ratio (uACR) Testing Patterns

Key Points

Assess CKD screening rates and testing patterns for eGFR and uACR in adults with Type 2 Diabetes.
Observational cohort study using Optum® Market Clarity data from 05/01/2021-12/31/2024.
Included adults with T2DM, no CKD diagnosis in the pre-index period, and ≥15 months follow-up.
Logistic regression models identified factors associated with CKD testing and uACR testing.
55% of patients underwent any CKD test in Year 1, with 55% receiving eGFR and only 29% being tested for uACR.
Testing varied by subgroup; increased uACR testing was noted in Year 2.
Patients with Medicaid, females, and racial minorities were less likely to receive any CKD test.

Abstract

Introduction and Objective: Despite guideline recommendations and quality measures such as the Kidney Health Evaluation in Diabetes (KED), CKD screening rates remain low in T2DM. This study assessed CKD screening, focusing on eGFR and uACR testing. Methods: This observational cohort study used Optum® Market Clarity data (05/01/2021-12/31/2024). Adults (≥18 years) with T2DM between 05/01/2021-09/30/2023 with the index date as the earliest diagnosis in the observation period,), no CKD diagnosis or lab evidence in the 12-month pre-index period, and ≥15 months of follow-up were included. CKD testing was defined as any eGFR, UACR, or other albuminuria from claims or EHR. Testing was assessed in Year 1 (0-15 months) and Year 2 (16-30 months, among those with ≥30 months follow-up). Separate logistic regression models identified factors associated with any CKD test and UACR test. Results: A total of 884,614 patients (52% female; median age 63 years) were included. In Year 1, 55% had any CKD test: 55% eGFR, 29% uACR, and 29% had both. Testing pattern varied by subgroup and uACR test increased in Year 2. Patients with Medicaid (vs. commercial), females, and racial minorities were less likely to receive any CKD test. Patients with Medicare/Medicaid, females, younger age, and higher Elixhauser Index were less likely to receive uACR test Conclusion: CKD screening among T2DM patients is suboptimal, particularly uACR. Greater adherence to ADA/KDIGO recommendations for eGFR and uACR testing is needed to enable earlier CKD detection, intervention, and potentially improve outcomes. Disclosure Y. Han: None. S. Chatterjee: Employee; Current; Boehringer Ingelheim International GmbH. L. Bengtson: Employee; Current; Boehringer Ingelheim Pharmaceuticals Inc. A. Nguyen: None. B.M. Donato: Employee; Current; Boehringer Ingelheim International GmbH. S. Corman: None. C.M. Shay: Employee; Current; Boehringer Ingelheim International GmbH.

Demander à l'IA

Bookmark

Cite This Study

HAN et al. (Fri,) studied this question.

synapsesocial.com/papers/6a250b707def13d035e1b641 https://doi.org/https://doi.org/10.2337/db26-1408-p

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Demander à l'IA

Bookmark